SJY26

SJY26 is a PI3K/HDAC dual-target inhibitor with IC50s of 0.59 nM (PI3Kα and PI3Kδ), 2.02 nM (PI3Kγ), 12.69 nM (PI3Kβ) and 114 nM (HDAC1) . SJY26 exhibits potent broad-spectrum anti-proliferative activity, and is particularly sensitive to Jurkat and PC9R cells. SJY26 inhibited the migration of PC9R cells, arrested the cell cycle and induced cell apoptosis. SJY26 reduces AKT phosphorylation, and decreases histone H3 deacetylation (Ac-H3) . SJY26 can be used for the studies of non-small cell lung cancer and leukemia[1].

Product Specifications

UNSPSC

12352005

Target

Akt; HDAC; Histone Methyltransferase; PI3K

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR

Field of Research

Cancer

Smiles

O=C(C1=CC=NC2=CC=C(C3=CC(NS(=O)(C4=CC=C(F)C=C4F)=O)=C(OC)N=C3)C=C12)NC5=CC=C(C(NC6=CC=CC=C6N)=O)C=C5

Molecular Formula

C35H26F2N6O5S

Molecular Weight

680.68

References & Citations

[1]Sun J, et al. Design, synthesis and bioactive evaluation of novel quinoline-linked sulfonamide-pyridine derivatives as PI3K/HDAC dual-target inhibitors. Eur J Med Chem. 2025 Sep 17;301:118170.